Who Owns Sisram Medical Company?

Sisram Medical Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Sisram Medical?

Sisram Medical, a global leader in aesthetic and minimally invasive solutions, went public on the Hong Kong Stock Exchange in September 2017. Established in 2013 to acquire Alma, a company founded in 2000, Sisram Medical aims to be a worldwide wellness brand.

With a market capitalization around US$426 million as of August 2025 and fiscal year 2024 revenues of US$349 million, the company's ownership significantly influences its strategic direction and global reach.

The ownership structure of Sisram Medical is primarily characterized by a majority stake held by a major Chinese healthcare group. This significant holding shapes the company's strategic decisions and its expansion initiatives across more than 110 countries and regions, offering a diverse portfolio including laser and radiofrequency technologies, as seen in the Sisram Medical PESTEL Analysis.

Sisram Medical Ltd was incorporated in Israel on April 25, 2013, primarily to acquire Alma Lasers, which was founded in 2000. The establishment of Sisram Medical was driven by a significant investment from Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma), a prominent Chinese healthcare group.

Early Investment in Alma Lasers

In 2013, a consortium led by Fosun Pharma invested approximately US$240 million to acquire a 96% stake in Alma Lasers.

Sisram Medical Incorporation

Sisram Medical Ltd was formally incorporated on April 25, 2013, serving as the holding company for the Alma Lasers acquisition.

Fosun Pharma's Initial Stake

Prior to its public listing, Fosun Pharma held a majority 66% stake in Sisram Medical.

Pre-IPO Capitalization

Before its 2017 IPO, 129,051,352 shares were allotted for an investment of US$146.92 million to early backers.

Early Stakeholders

Ample Up Limited, Chindex Medical Limited, and Magnificent View Investments Limited were key entities representing early backers and strategic partners.

Alma Lasers Founding

Alma Lasers, the operational core of Sisram Medical, was originally founded in the year 2000.

The corporate structure established for Sisram Medical reflected Fosun Pharma's strategic intent to integrate Alma Lasers' expertise within its broader wellness ecosystem. There is no public record detailing individual founder shareholdings of Alma Lasers at its initial founding in 2000, nor any specific early ownership disputes or buyouts concerning Alma Lasers prior to its acquisition by the Fosun-led consortium. Understanding this early ownership is crucial for grasping the Competitors Landscape of Sisram Medical.

Sisram Medical Ownership Genesis

Sisram Medical's inception was a strategic move by Fosun Pharma to consolidate its position in the medical aesthetics market through the acquisition of Alma Lasers.

• Fosun Pharma acted as the primary architect and lead investor.
• The acquisition of Alma Lasers was a pivotal event in Sisram Medical's formation.
• Early capitalization involved significant investments from specific corporate entities.
• Fosun Pharma's substantial initial stake underscored its controlling interest.

Sisram Medical SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The ownership structure of Sisram Medical saw a significant shift with its Initial Public Offering (IPO) on the Hong Kong Stock Exchange in September 2017. This event raised substantial capital and established its public trading status.

Following its IPO, Sisram Medical's ownership is primarily characterized by the continued significant stake held by its corporate parent, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. As of early June 2025, institutional investors collectively own a notable portion of the company's shares, indicating broad market participation and confidence. These institutional holdings, alongside the strategic backing from Fosun, play a crucial role in shaping the company's direction, particularly in its expansion into new product areas and global markets, as detailed in the Target Market of Sisram Medical.

Key Stakeholders in Sisram Medical

The ownership of Sisram Medical is anchored by its parent company, with a notable presence of institutional investors. These stakeholders influence the company's strategic initiatives and market positioning.

• Fosun Pharma: Remains the indirect majority shareholder, holding approximately 52.96% post-IPO.
• Ample Up Limited: Identified as a major shareholder as of March 2025.
• Fosun International Holdings Limited: The ultimate holding company.
• Mr. Guo Guangchang: The ultimate controlling shareholder.
• Institutional Investors: Including WisdomTree Funds and Segall Bryant & Hamill International Small Cap Fund Retail Class, collectively holding 1,308,064 shares as of June 3, 2025.
• Other Institutional Shareholders: Such as China Universal Asset Management, China Asset Management, Citic Securities, and HuaAn Fund Management.

Sisram Medical PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Board of Directors at Sisram Medical is structured to reflect significant ownership interests while upholding governance standards. As of August 2025, Mr. Liu Yi leads the board as Chairman and Executive Director, with Mr. Lior Dayan serving as Chief Executive Officer. Key management figures, including CFOs and IR directors, also play vital roles in the company's oversight.

While the precise representation of major shareholders, such as the primary controlling entity, on the board is not exhaustively detailed in public summaries, it is standard practice for majority shareholders to hold significant board seats. This ensures alignment between ownership and strategic direction. For companies listed on the Hong Kong Stock Exchange, the typical governance model follows a one-share-one-vote principle, meaning voting power is generally proportional to shareholding, unless specific classes of shares with differential rights are in place. There have been no reported governance challenges or significant shifts in control dynamics through activist campaigns or proxy battles in the 2024-2025 period, suggesting a stable ownership and management structure for Sisram Medical.

Board Governance and Shareholder Influence

The board composition at Sisram Medical is designed to balance operational leadership with strategic oversight, reflecting the influence of its major shareholders. This structure is crucial for maintaining effective corporate governance and aligning management decisions with the interests of those who own Sisram Medical.

• Board leadership ensures strategic alignment.
• Executive management drives operational execution.
• Financial oversight is maintained by dedicated CFOs.
• Investor relations are managed to ensure transparency.
• The corporate structure supports shareholder interests.

Sisram Medical Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past three to five years, Sisram Medical has navigated significant shifts, including strategic acquisitions and a pronounced move towards direct sales. These changes reflect an evolving market and the company's ambition to broaden its consumer wellness offerings.

The company's financial performance in recent periods shows a slight revenue dip in 2024, yet an improvement in gross profit margin and a substantial increase in direct sales revenue. This pivot to direct sales, reaching 87% in 2024, indicates a successful strategy to engage customers more directly. The injectables business has emerged as a key growth area, with a remarkable 218.1% year-over-year revenue increase to US$14.4 million in the first half of 2025. While overall H1 2025 revenue saw a marginal 1.9% decrease to US$165.5 million, and adjusted net profit declined by 28.1% to US$12.0 million, the company's strategic focus remains on high-value segments and market expansion. A notable acquisition in this period was the 60% purchase of PhotonMed, a China-based distributor of energy-based devices, in early 2023, aimed at bolstering market presence. The company's leadership has outlined plans for 2025 to accelerate product commercialization, advance its injectables portfolio, and expand its global footprint through direct-sales offices, with the goal of creating an integrated wellness ecosystem. This strategic direction is informed by industry trends favoring direct sales and diversification into premium offerings, as detailed in the Brief History of Sisram Medical.

Revenue Shift to Direct Sales

Sisram Medical has significantly increased its direct sales revenue, reaching 87% in 2024. This strategic move enhances customer engagement and market control.

Injectables Business Growth

The injectables segment has become a major growth driver, reporting a 218.1% revenue increase in H1 2025. This highlights the company's focus on high-value product lines.

Strategic Acquisition in China

In early 2023, the company acquired a 60% stake in PhotonMed, a Chinese distributor of energy-based devices. This acquisition aims to expand market reach and distribution capabilities.

Global Expansion and Ecosystem Focus

Future plans for 2025 include expanding direct-sales offices globally. The company aims to build a comprehensive wellness ecosystem by integrating its product offerings.

Sisram Medical Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔